Unknown

Dataset Information

0

Evaluating the RIST Molecular-Targeted Regimen in a Three-Dimensional Neuroblastoma Spheroid Cell Culture Model.


ABSTRACT:

Background

The outcome for patients with high-risk neuroblastoma remains poor and novel treatment strategies are urgently needed. The RIST protocol represents a novel metronomic and multimodal treatment strategy for high-risk neuroblastoma combining molecular-targeted drugs as 'pre-treatment' with a conventional chemotherapy backbone, currently evaluated in a phase II clinical trial. For preclinical drug testing, cancer cell growth as spheroid compared to mo-nolayer cultures is of advantage since it reproduces a wide range of tumor characteristics, including the three-dimensional architecture and cancer stem cell (CSC) properties. The objective of this study was to establish a neuroblastoma spheroid model for the rigorous assessment of the RIST treatment protocol.

Methods

Evaluation of CSC marker expression was performed by mRNA and protein analysis and spheroid viability by luminescence-based assays. Aberrant expression of RNA-binding protein La in neuroblastoma was assessed by tissue microarray analysis and patients' data mining.

Results

Spheroid cultures showed increased expression of a subgroup of CSC-like markers (CXCR4, NANOG and BMI) and higher Thr389 phosphorylation of the neuroblastoma-associated RNA-binding protein La when compared to monolayer cultures. Molecular-targeted 'pre-treatment' of spheroids decreased neoplastic signaling and CSC marker expression.

Conclusions

The RIST treatment protocol efficiently reduced the viability of neuroblastoma spheroids characterized by advanced CSC properties.

SUBMITTER: Kaess C 

PROVIDER: S-EPMC10046822 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluating the RIST Molecular-Targeted Regimen in a Three-Dimensional Neuroblastoma Spheroid Cell Culture Model.

Kaess Carina C   Matthes Marie M   Gross Jonas J   Waetzig Rebecca R   Heise Tilman T   Corbacioglu Selim S   Sommer Gunhild G  

Cancers 20230314 6


<h4>Background</h4>The outcome for patients with high-risk neuroblastoma remains poor and novel treatment strategies are urgently needed. The RIST protocol represents a novel metronomic and multimodal treatment strategy for high-risk neuroblastoma combining molecular-targeted drugs as 'pre-treatment' with a conventional chemotherapy backbone, currently evaluated in a phase II clinical trial. For preclinical drug testing, cancer cell growth as spheroid compared to mo-nolayer cultures is of advant  ...[more]

Similar Datasets

| S-EPMC4663656 | biostudies-literature
| S-EPMC6171656 | biostudies-literature
| S-EPMC7811591 | biostudies-literature
| S-EPMC4942491 | biostudies-literature
| S-EPMC5491519 | biostudies-literature
| S-EPMC2804865 | biostudies-literature
| S-EPMC10937281 | biostudies-literature
| S-EPMC8399878 | biostudies-literature
| S-EPMC3315752 | biostudies-literature
| S-EPMC8361632 | biostudies-literature